Atara Investors Urged to Seek Lead Role in Securities Case Ahead of Deadline

Plaintiffs allege undisclosed manufacturing problems alongside ALLELE flaws undermined FDA approval for tabelecleucel.

Overview

Rosen Law Firm and The Law Offices of Frank R. Cruz are recruiting investors to seek lead‑plaintiff status before the court’s deadline.
The case covers people who bought Atara shares from May 20, 2024 through January 9, 2026.
The complaint claims Atara failed to disclose manufacturing problems and limits in its single‑arm ALLELE study, making FDA approval unlikely.
Plaintiffs say those problems drew tougher FDA scrutiny and put trials at risk, which they argue led to investor losses when details surfaced.
No class has been certified, and the firms note investors are not represented unless they retain counsel or the court appoints one.